Samsung Biologics Reports Q2 Revenue Up 30.2%, Operating Profit Up 22.9% on July 23

Samsung Biologics posted Q2 2026 revenue of 1.32 trillion Korean won and operating profit of 586.4 billion Korean won on July 23, up 30.2% and 22.9% year-over-year respectively. The company maintained operating margins above 40% despite upfront costs for its newly operational Plant 5 and Rockville, U.S. facility. Despite union strikes causing some production disruptions, Samsung Biologics expressed confidence in achieving its full-year revenue growth guidance of 15-20%.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments